ABSTRACT
Background Brain-based interventions are needed to address persistent relapse in alcohol use disorder (AUD). Neuroimaging evidence suggests higher fronto-striatal connectivity as well as higher within-network connectivity of theoretically defined addiction networks is associated with reduced relapse rates and extended abstinence during follow-up periods.
Objective/Hypothesis A longitudinal randomized double-blind sham-controlled clinical trial investigated whether a non-invasive neuromodulation intervention delivered during early abstinence can (i) modulate connectivity of addiction networks supporting abstinence and (ii) improve relapse rates. Hypotheses: Active transcranial direct current stimulation (tDCS) will (i) increase connectivity of addiction networks known to support abstinence and (ii) reduce relapse rates.
Methods Short-term abstinent AUD participants (n=60) were assigned to 5 days of either active tDCS or sham during cognitive training. Causal discovery analysis (CDA) examined the directional influence from left dorsolateral prefrontal cortex (LDLPFC, stimulation site) to addiction networks that support abstinence.
Results Active tDCS had an effect on the average strength of CDA-determined connectivity from LDLPFC to the incentive salience and negative emotionality addiction networks - increasing in the active tDCS group and decreasing in the sham group. Active tDCS had an effect on relapse rates 1-month following the intervention, with lower probability of relapse in the active tDCS vs. sham groups. Active tDCS showed an unexpected sex-dependent effect on relapse rates.
Conclusion Our results suggest that LDLPFC stimulation delivered during early abstinence has an effect on addiction networks supporting abstinence and on relapse rates. The unexpected sex-dependent neuromodulation effects need to be further examined in larger clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02168400
Funding Statement
This work was supported by the National Institute of Health (K01AA026349 to M.F and J.C.; UL1TR002494 to J.C.; MH116987 to M.F. and K.O.L.; UG3DA048508 and R01DA038984 to K.O.L.; UL1TR000114 to EK; P41EB027061, P30NS076408, S10OD017974-01 to CMRR) and the Westlake Wells Foundation to J.C.. The opinions and assertions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the National Institute of Health or the Westlake Wells Foundation. All authors have declared that there are no competing or potential conflicts of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board at the University of Minnesota
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
